Safety and stable survival of stem-cell-derived retinal organoid for 2 years in patients with retinitis pigmentosa

被引：22

作者：

Hirami, Yasuhiko ^{[1
,2
,3
]}

Mandai, Michiko ^{[1
,3
,4
,5
]}

Sugita, Sunao ^{[1
,3
]}

Maeda, Akiko ^{[1
,3
,4
]}

Maeda, Tadao ^{[1
,4
]}

Yamamoto, Midori ^{[1
,4
]}

Uyama, Hirofumi ^{[1
,2
]}

Yokota, Satoshi ^{[1
,2
,3
]}

Fujihara, Masashi ^{[1
,2
,3
]}

Igeta, Masataka ^{[6
]}

Daimon, Takashi ^{[6
]}

Fujita, Kanako ^{[4
]}

Ito, Tomoko ^{[4
]}

Shibatani, Naoki ^{[4
]}

Morinaga, Chikako ^{[5
]}

Hayama, Tetsuya

Nakamura, Aya ^{[8
]}

Ueyama, Kazuki ^{[8
]}

Ono, Keiichi ^{[8
]}

Ohara, Hidetaka ^{[9
]}

Fujiwara, Masayo ^{[7
]}

Yamasaki, Suguru ^{[7
]}

Watari, Kenji ^{[7
]}

Bando, Kiyoko ^{[9
]}

Kawabe, Keigo ^{[9
]}

Ikeda, Atsushi ^{[7
]}

Kimura, Toru ^{[7
,9
]}

Kuwahara, Atsushi ^{[7
]}

Takahashi, Masayo ^{[1
]}

Kurimoto, Yasuo ^{[1
,2
,3
]}

机构：

[1] Kobe City Eye Hosp, Dept Ophthalmol, Kobe 6500047, Japan

[2] Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Kobe 6500047, Japan

[3] RIKEN Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Kobe 6500047, Japan

[4] Kobe City Eye Hosp, Res Ctr, Kobe 6500047, Japan

[5] RIKEN Program Drug Discovery & Med Technol Platfor, Yokohama 2300045, Japan

[6] Hyogo Med Univ, Dept Biostat, Nishinomiya 6638501, Japan

[7] Sumitomo Pharm Co Ltd, Regenerat & Cellular Med Kobe Ctr, Kobe 6500047, Japan

[8] Sumitomo Pharm Co Ltd, Technol Res & Dev Div, Kobe 6500047, Japan

[9] Sumitomo Pharm Co Ltd, Regenerat & Cellular Med Off, Tokyo 1036012, Japan

来源：

CELL STEM CELL | 2023年 / 30卷 / 12期

关键词：

TRANSPLANTATION; VISION; SHEETS;

D O I：

10.1016/j.stem.2023.11.004

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

Transplantation of induced pluripotent stem cell (iPSC)-derived retinal organoids into retinal disease animal models has yielded promising results, and several clinical trials on iPSC-derived retinal pigment epithelial cell transplantation have confirmed its safety. In this study, we performed allogeneic iPSC-derived retinal orga-noid sheet transplantation in two subjects with advanced retinitis pigmentosa (jRCTa050200027). The pri-mary endpoint was the survival and safety of the transplanted retinal organoid sheets in the first year post-transplantation. The secondary endpoints were the safety of the transplantation procedure and visual function evaluation. The grafts survived in a stable condition for 2 years, and the retinal thickness increased at the transplant site without serious adverse events in both subjects. Changes in visual function were less pro-gressive than those of the untreated eye during the follow-up. Allogeneic iPSC-derived retinal organoid sheet transplantation is a potential therapeutic approach, and the treatment's safety and efficacy for visual function should be investigated further.

引用

页码：1585 / 1596.e6

页数：19

共 50 条

[1] Induced pluripotent stem cell derived retinal organoid sheets for regenerative therapy in patients with end-stage retinitis pigmentosa
Mandai, Michiko
Hirami, Yasuhiko
Sugita, Sunao
Maeda, Akiko
Maeda, Tadao
Yamamoto, Midori
Uyama, Hirofumi
Yokota, Satoshi
Fujihara, Masashi
Igeta, Masataka
Daimon, Takashi
Fujita, Kanako
Ito, Tomoko
Takahashi, Masayo
Kurimoto, Yasuo
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
[2] Adaptive Optics Optical Coherence Tomography Analysis of Induced Pluripotent Stem Cell-Derived Retinal Organoid Transplantation in Retinitis Pigmentosa
Ishikura, Masaharu
Muraoka, Yuki
Hirami, Yasuhiko
Tu, Hung-Ya
Mandai, Michiko
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
[3] Turning point of organoid transplantation: first-in-human trial of iPSC-derived retinal organoid grafting in patients with retinitis pigmentosa
Chang-Jun Zhang
Zi-Bing Jin
Science China Life Sciences, 2024, 67 : 1082 - 1084
[4] Turning point of organoid transplantation: first-in-human trial of iPSC-derived retinal organoid grafting in patients with retinitis pigmentosa
Zhang, Chang-Jun
Jin, Zi-Bing
SCIENCE CHINA-LIFE SCIENCES, 2024, 67 (05) : 1082 - 1084
[5] Turning point of organoid transplantation: first-in-human trial of iPSC-derived retinal organoid grafting in patients with retinitis pigmentosa
Chang-Jun Zhang
Zi-Bing Jin
Science China(Life Sciences), 2024, 67 (05) : 1082 - 1084
[6] Human iPSC derived disease model of USH2A-associated retinitis pigmentosa and the retinal organoid in early stage
Chen, Jiansu
Guo, Yonglong
Yu, Quan
Cui, Zekai
Zhang, Jun
Ma, Hongjie
Tang, Shibo
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
[7] Patient-derived Retinal Organoid as a Disease Model for Adult-Onset Retinitis Pigmentosa 1
Berber, Patricia
Milenkovic, Andrea
Kiel, Christina
Michaelis, Lisa
Strunz, Tobias
Brandl, Caroline
Weber, Bernhard
EUROPEAN JOURNAL OF HUMAN GENETICS, 2023, 31 : 79 - 79
[8] Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients
Liu, Yong
Chen, Shao Jun
Li, Shi Ying
Qu, Ling Hui
Meng, Xiao Hong
Wang, Yi
Xu, Hai Wei
Liang, Zhi Qing
Yin, Zheng Qin
STEM CELL RESEARCH & THERAPY, 2017, 8
[9] Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients
Yong Liu
Shao Jun Chen
Shi Ying Li
Ling Hui Qu
Xiao Hong Meng
Yi Wang
Hai Wei Xu
Zhi Qing Liang
Zheng Qin Yin
Stem Cell Research & Therapy, 8
[10] Improving the safety of stem-cell-derived beta cell transplantation with an inducible safety switch
Chu, Simon N.
Amirruddin, N. Shabrina
Sharma, Devesh K.
Sierra, Isabel C.
Stock, Peter G.
Sneddon, Julie B.
Cromer, M. Kyle
TRANSPLANTATION, 2023, 107 (10) : 165 - 166

← 1 2 3 4 5 →